CAPRICOR THERAPEUTICS, INC. short interest in 2020
In 2020, CAPRICOR THERAPEUTICS, INC.'s disclosed short interest ran from 1.13% of shares outstanding on 15 Jan 2020 to 3.71% on 31 Dec 2020, a change of +2.58 percentage points. The year's high was 10.46% on 14 Aug 2020 and its low 0.61% on 13 Mar 2020, averaging 4.47% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 3.73 days on 30 Oct 2020. Full history: CAPRICOR THERAPEUTICS, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 1.13% (15 Jan 2020)
- End of year
- 3.71% (31 Dec 2020)
- Change
- +2.58 pp
- High
- 10.46% (14 Aug 2020)
- Low
- 0.61% (13 Mar 2020)
- Average
- 4.47%
- Highest days to cover
- 3.73 (30 Oct 2020)
- SEC filings marked
- 9
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 1.13% | 1.00 | |
| 28 Feb 2020 | 0.69% | 1.00 | |
| 13 Mar 2020 | 0.61% | 1.00 | |
| 31 Mar 2020 | 0.76% | 1.00 | results (8-K), 10-K filed |
| 15 Apr 2020 | 0.83% | 1.00 | |
| 29 May 2020 | 1.30% | 1.00 | results (8-K), 10-Q filed |
| 15 Jun 2020 | 3.08% | 1.00 | |
| 30 Jun 2020 | 4.97% | 1.00 | |
| 15 Jul 2020 | 5.01% | 1.00 | |
| 14 Aug 2020 | 10.46% | 1.00 | results (8-K), 10-Q filed |
| 31 Aug 2020 | 9.75% | 1.46 | |
| 15 Sep 2020 | 7.40% | 1.61 | |
| 30 Sep 2020 | 7.30% | 1.00 | |
| 15 Oct 2020 | 6.71% | 3.09 | |
| 30 Oct 2020 | 6.03% | 3.73 | |
| 13 Nov 2020 | 6.08% | 1.92 | results (8-K), results (8-K), 10-Q filed |
| 30 Nov 2020 | 5.32% | 2.58 | |
| 15 Dec 2020 | 3.74% | 1.80 | |
| 31 Dec 2020 | 3.71% | 1.55 |
See also: CAPRICOR THERAPEUTICS, INC.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.